Analyst: Buy Monsanto Ahead of Bayer Acquisition, Because a Higher Offer is Coming

Image of blue arrow pointing upSeed and agricultural products maker Monsanto Company (NYSE:MON) on Monday received a big upgrade from analysts at Monness Crespi & Hardt.

The firm lifted its rating on MON from Neutral to Buy and set a $130 price target, suggesting a 22% upside from the stock’s Friday closing price.

Monness Crespi & Hardt said its confidence is growing that Germany-based Bayer AG will get a deal done to buy Monsanto soon, at a much higher price point.

MON recently opened its books up to Bayer, which likely means a larger bid is on the way. Bayer had previously made a $122 per-share offer, which equates to about $62 billion in cash.

The firm also noted that it’s probably in both companies’ self-interest to complete a deal now, and multiple reports suggest progress from both sides. Accordingly, the analyst sees a deal around the $130 per share level, hence the price target set at that level.

If completed, the takeover would be the largest deal ever made by a German company.

Monsanto shares fell $0.50 (-0.47%) to $106.43 in Monday afternoon trading. MON has risen 8.18% since the start of 2016, which is roughly in-line with the benchmark S&P 500 index.


You are viewing an abbreviated republication of ETF Daily News content. You can find full ETF Daily News articles on (

Powered by WPeMatico